Company Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally.
The company’s commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease; and DMX-200, a small molecule inhibitor of the chemokine receptor 2 that is in a pivotal Phase 3 study for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease.
It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold; and Dimerix Limited for the commercialization of DMX-200 for the treatment of FSGS and other indications.
Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
| Country | United States |
| Founded | 2002 |
| IPO Date | May 31, 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 511 |
| CEO | Bradley Campbell |
Contact Details
Address: 47 Hulfish Street Princeton, New Jersey 08542 United States | |
| Phone | 609 662 2000 |
| Website | amicusrx.com |
Stock Details
| Ticker Symbol | FOLD |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001178879 |
| CUSIP Number | 03152W109 |
| ISIN Number | US03152W1099 |
| Employer ID | 20-0422823 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Bradley L. Campbell M.B.A. | Chief Executive Officer, President and Director |
| Simon Nicolas Reade Harford | Chief Financial Officer |
| Ellen S. Rosenberg J.D. | Chief Legal Officer and Corporate Secretary |
| David M. Clark | Chief People Officer |
| Dr. Jeffrey P. Castelli Ph.D. | Chief Development Officer |
| Samantha L. Prout | Chief Accounting Officer and Controller |
| Dr. Jill Weimer Ph.D. | Chief Science Officer |
| Andrew Faughnan | Vice President of Investor Relations |
| Patrik S. Florencio Esq. | Global Chief Compliance and Risk Officer |
| Brendan McEvoy | Executive Director of External Communications |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 27, 2026 | POS AM | Post-Effective amendments for registration statement |
| Apr 27, 2026 | POS AM | Post-Effective amendments for registration statement |
| Apr 27, 2026 | POS AM | Post-Effective amendments for registration statement |
| Apr 27, 2026 | POS AM | Post-Effective amendments for registration statement |
| Apr 27, 2026 | POS AM | Post-Effective amendments for registration statement |
| Apr 27, 2026 | POS AM | Post-Effective amendments for registration statement |
| Apr 27, 2026 | POS AM | Post-Effective amendments for registration statement |
| Apr 27, 2026 | POS AM | Post-Effective amendments for registration statement |
| Apr 27, 2026 | 8-K | Current Report |
| Apr 27, 2026 | POSASR | Filing |